Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil 10.11.2022, 07:01 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse

Evolva Holding SA / Key word(s): Regulatory Approval
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil

10.11.2022 / 07:01 CET/CEST


Reinach, 10 November 2022 – Evolva (SIX: EVE) a pioneer in the field of natural molecules and industrial biotech, has received approval for its Veri-teTM  Resveratrol from the Brazilian Ministry of Agriculture, Livestock and Supply for animal nutrition and health, covering all animal species and all applications, including veterinary supplements.

The approval is an important milestone as it opens up exciting opportunities in the Brazilian market where Evolva already has regulatory approval for use of its Veri-teTM Resveratrol for use in dietary supplements for humans. Under the branding of Veri-teTM PETS, the formulations will be marketed by Evolva’s existing Brazilian distribution partner, Tovani Benzaquen Ingredients (”Tovani”).

Anne De Vos, Chief Commercial Officer of Evolva, comments: ”Following initial sales with our Veri-teTM Resveratrol product offering for use in dietary supplements for humans, the approval and registration for use in dietary supplements and feed for all animal species significantly expands the addressable market for us in Brazil. Veri-teTM Resveratrol today is the main pillar of Evolva’s Health Ingredients business and a key contributor to our ambition to significantly boost growth. We will work with our trusted partner Tovani to jointly address this additional market potential.”

 

 

Important dates

09 March 2023 Full-year 2022 results

18 April 2023  Annual General Meeting

 

 

Contact

Doris Rudischhauser

Head of Investor Relations and Corporate Communications

+41 79 410 81 88

dorisr@evolva.com

 

About Veri-teTM Resveratrol

Resveratrol is a polyphenolic compound that occurs naturally in plants such as grapes, peanuts, cranberries and other berries, albeit at low concentrations. Evolva’s Veri-teTM Resveratrol is a nature-based high-purity ingredient, made via fermentation, which ensures a stable, traceable and reliable supply. The ingredient is offered in different formats such as a cold-water dispersible or an oil and water-soluble resveratrol and is sold for use in dietary supplements, functional beverages, cosmetics, pharma applications and animal health markets.

 

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at evolva.com and connect with us on LinkedIn.

For Evolva multimedia content, please visit: evolva.com/multimedia-library.

 

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

 

 

 



End of Media Release


Language: English
Company: Evolva Holding SA
Duggingerstrasse 23
4153 Reinach
Switzerland
Phone: +41 61 485 20 00
Internet: www.evolva.com
ISIN: CH0021218067
Valor: 2121806
Listed: SIX Swiss Exchange
EQS News ID: 1483821

 
End of News EQS News Service

1483821  10.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1483821&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer